$BRAC
Broad Capital Acquisition Corp Stock $brac

$brac Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017112 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$230.0K	$1.231M	$459.4K
YoY Change	96.06%	167.84%
Operating Profit	-$225.2K	-$1.231M	-$459.5K
YoY Change	91.96%	167.78%
Interest Expense	$23.35K	$6.946K	$39.95K
YoY Change	-78.47%	-82.61%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$475.2K	-$509.7K	-$419.5K
YoY Change	-5469.15%	21.51%
Income Tax	$135.1K	$142.6K
% Of Pretax Income	28.43%
Net Earnings	$340.1K	-$652.3K	-$419.5K
YoY Change	-3942.73%	55.51%
Net Earnings / Revenue
Basic Earnings Per Share	$0.04	-$0.05	-$0.04
Diluted Earnings Per Share	$0.04	-$0.05	-$28.95K
COMMON SHARES
Basic Shares Outstanding	2.991M shares	2.991M shares	11.90M shares
Diluted Shares Outstanding	8.597M shares	13.49M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.70M	$62.32M	$639.4K
YoY Change	-52.89%	9647.31%
Cash & Equivalents	$52.15K	$94.30K	$639.3K
Short-Term Investments	$48.65M	$62.23M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$52.15K	$94.30K	$639.4K
YoY Change	-91.62%	-85.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$48.70M	$62.23M	$102.6M
YoY Change	-52.61%	-39.38%
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$48.65M	$62.23M	$102.6M
YoY Change	-52.65%	-39.38%
TOTAL ASSETS
Total Short-Term Assets	$52.15K	$94.30K	$639.4K
Total Long-Term Assets	$48.65M	$62.23M	$102.6M
Total Assets	$48.70M	$62.32M	$103.3M
YoY Change	-52.89%	-39.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$749.9K	$927.2K
YoY Change	9898.33%
Accrued Expenses	$674.5K	$565.1K	$47.50K
YoY Change	380.71%	1089.74%
Deferred Revenue
YoY Change
Short-Term Debt	$2.200M	$1.132M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.193M	$3.102M	$47.50K
YoY Change	2736.98%	6430.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.600M	$3.556M	$3.556M
YoY Change	1.25%	0.0%
Total Long-Term Liabilities	$3.600M	$3.556M	$3.556M
YoY Change	1.25%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.193M	$3.102M	$47.50K
Total Long-Term Liabilities	$3.600M	$3.556M	$3.556M
Total Liabilities	$7.749M	$6.657M	$3.603M
YoY Change	109.24%	84.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.084M	-$6.086M
YoY Change	141.54%
Common Stock	$3.00	$3.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.084M	-$6.086M	-$2.924M
YoY Change
Total Liabilities & Shareholders Equity	$48.70M	$62.32M	$103.3M
YoY Change	-52.89%	-39.66%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$340.1K	-$652.3K	-$419.5K
YoY Change	-3942.73%	55.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$320.0K	-$740.4K	-$563.2K
YoY Change	1783.46%	31.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$14.30M	$42.66M	-$102.6M
YoY Change		-141.58%
Cash From Investing Activities	$14.30M	-$42.66M	-$102.6M
YoY Change		-58.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-14.03M	-$42.22M	103.8M
YoY Change		-140.67%
NET CHANGE
Cash From Operating Activities	-320.0K	-$740.4K	-563.2K
Cash From Investing Activities	14.30M	-$42.66M	-102.6M
Cash From Financing Activities	-14.03M	-$42.22M	103.8M
Net Change In Cash	-50.00K	-$85.63M	637.2K
YoY Change	194.29%	-13538.41%
FREE CASH FLOW
Cash From Operating Activities	-$320.0K	-$740.4K	-$563.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	BRAC	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption		usd
CY2023Q1	BRAC	Deferred Offering Costs Paid For By Promissory Note Related Party DeferredOfferingCostsPaidForByPromissoryNoteRelatedParty		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001865120
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	BRAC	Extension Loan ExtensionLoan		usd
CY2022Q4	BRAC	Working Capital Loan WorkingCapitalLoan		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q1	BRAC	Franchise Tax Expenses FranchiseTaxExpenses		usd
CY2022Q1	us-gaap	Interest Expense InterestExpense		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity		usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable		usd
CY2022Q1	BRAC	Increase Decrease In Franchise Tax Expenses IncreaseDecreaseInFranchiseTaxExpenses		usd
CY2022Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments		usd
CY2022Q1	BRAC	Interest Withdraw From Trust Account InterestWithdrawFromTrustAccount		usd
CY2022Q1	BRAC	Proceeds From Working Capital Loan ProceedsFromWorkingCapitalLoan		usd
CY2022Q1	BRAC	Proceeds From Extension Loan ProceedsFromExtensionLoan		usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022Q1	BRAC	Extension Funds Attributable To Common Stock Subject To Redemption ExtensionFundsAttributableToCommonStockSubjectToRedemption		usd
CY2022Q1	BRAC	Accretion Of Common Stock Subject To Redemption AccretionOfCommonStockSubjectToRedemption		usd
CY2023Q1	BRAC	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2022Q4	BRAC	Working Capital Loan WorkingCapitalLoan		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41212
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BROAD CAPITAL ACQUISITION CORP
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3382967
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5345 Annabel Lane
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Plano
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75093
CY2023Q1	dei	City Area Code CityAreaCode	(469)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	951-3088
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2990897	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94300	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391924	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	94300	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	391924	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	62225137	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	104162029	usd
CY2023Q1	us-gaap	Assets Assets	62319437	usd
CY2022Q4	us-gaap	Assets Assets	104553953	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	565128	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	648885	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	927217	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	200028	usd
CY2023Q1	BRAC	Franchise Tax Payable FranchiseTaxPayable	48785	usd
CY2022Q4	BRAC	Franchise Tax Payable FranchiseTaxPayable	195138	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	428241	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	285662	usd
CY2023Q1	BRAC	Extension Loan ExtensionLoan	1112177	usd
CY2023Q1	BRAC	Working Capital Loan WorkingCapitalLoan	20250	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3101798	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1329713	usd
CY2023Q1	BRAC	Deferred Underwriter Commission DeferredUnderwriterCommission	3555674	usd
CY2022Q4	BRAC	Deferred Underwriter Commission DeferredUnderwriterCommission	3555674	usd
CY2023Q1	us-gaap	Liabilities Liabilities	6657472	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4885387	usd
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5931608	shares
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.41
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10159069	shares
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.23
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	61748111	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	103962029	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2990897	shares
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5931608	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10159069	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6086149	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4293466	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6086146	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4293463	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62319437	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	104553953	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1181717	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	459413	usd
CY2023Q1	BRAC	Franchise Tax Expenses FranchiseTaxExpenses	48785	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1230502	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-459513	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	6946	usd
CY2023Q1	BRAC	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	727731	usd
CY2022Q1	BRAC	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	39948	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-509717	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-419465	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	142579	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-652296	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-419465	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13485199	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11901642	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4905	usd
CY2022Q1	BRAC	Stock Issued During Period Value Sale Of Units In Initial Public Offering StockIssuedDuringPeriodValueSaleOfUnitsInInitialPublicOffering	101590690	usd
CY2022Q1	BRAC	Stock Issued During Period Value Common Stock Subject To Possible Redemption StockIssuedDuringPeriodValueCommonStockSubjectToPossibleRedemption	-101606597	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4511300	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2449040	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3555674	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-419465	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2923881	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4293463	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4293463	usd
CY2023Q1	BRAC	Common Stock Subject To Possible Redemption Price Per Share CommonStockSubjectToPossibleRedemptionPricePerShare	0.0625
CY2023Q1	BRAC	Additional Common Stock Subject To Possible Redemption AdditionalCommonStockSubjectToPossibleRedemption	-1112177	usd
CY2023Q1	BRAC	Remeasurement Of Common Stock Subject To Redemption RemeasurementOfCommonStockSubjectToRedemption	-28210	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-652296	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6086146	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6086146	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-652296	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-419465	usd
CY2023Q1	BRAC	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	727731	usd
CY2022Q1	BRAC	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount	39948	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	727189	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-83757	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-103827	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	142579	usd
CY2023Q1	BRAC	Increase Decrease In Franchise Tax Expenses IncreaseDecreaseInFranchiseTaxExpenses	146353	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-740369	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-563240	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	43354304	usd
CY2023Q1	BRAC	Interest Withdraw From Trust Account InterestWithdrawFromTrustAccount	422495	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1112177	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	102606596	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42664622	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102606596	usd
CY2023Q1	BRAC	Common Stock Subject To Possible Redemption CommonStockSubjectToPossibleRedemption	-43354304	usd
CY2023Q1	BRAC	Proceeds From Working Capital Loan ProceedsFromWorkingCapitalLoan	20250	usd
CY2023Q1	BRAC	Proceeds From Extension Loan ProceedsFromExtensionLoan	1112177	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	99429074	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4511301	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	133357	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-42221877	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103807018	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-297624	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	637182	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	391924	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2164	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94300	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	639346	usd
CY2023Q1	BRAC	Extension Funds Attributable To Common Stock Subject To Redemption ExtensionFundsAttributableToCommonStockSubjectToRedemption	1112177	usd
CY2023Q1	BRAC	Accretion Of Common Stock Subject To Redemption AccretionOfCommonStockSubjectToRedemption	28210	usd
CY2022Q1	BRAC	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	3555674	usd
CY2022Q1	BRAC	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption	102606597	usd
CY2022Q1	BRAC	Deferred Offering Costs Paid For By Promissory Note Related Party DeferredOfferingCostsPaidForByPromissoryNoteRelatedParty	176	usd
CY2022Q1	BRAC	Underwriters Deferred Discount UnderwritersDeferredDiscount	31814	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	101000000	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.10
CY2023Q1	BRAC	Business Combination Condition Minimum Tangible Assets BusinessCombinationConditionMinimumTangibleAssets	5000001	usd
CY2022Q4	BRAC	Percentage Of The Public Shareholding To Be Redeemed In Case The Business Combination Is Not Consummated PercentageOfThePublicShareholdingToBeRedeemedInCaseTheBusinessCombinationIsNotConsummated	1	pure
CY2023Q1	us-gaap	Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities	100000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94300	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	133533	usd
CY2023Q1	BRAC	Working Capital Loan WorkingCapitalLoan	20250	usd
CY2023Q1	BRAC	Extension Loan ExtensionLoan	1112177	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zzzRZwsrGwAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zCENGMQkiTv2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	62225137	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	104162029	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zC8z4QTWtSJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zVgyVQuZo124">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zXP48wthqhY" title="Federal depository insurance coverage amount">250,000</span>. As of March 31, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.4pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q1	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	Each Unit consists of one share of common stock and one right to receive one-tenth (1/10) of one share of common stock upon the consummation of an initial business combination.
CY2023Q1	BRAC	Working Capital Loan WorkingCapitalLoan	20250	usd
CY2023Q1	BRAC	Working Capital Loan WorkingCapitalLoan	20250	usd
CY2023Q1	BRAC	Extension Loan ExtensionLoan	1112177	usd
CY2023Q1	BRAC	Extension Loan ExtensionLoan	1112177	usd
CY2023Q1	BRAC	Servicer Fees ServicerFees	30000	usd
CY2022	BRAC	Servicer Fees ServicerFees	110000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2990897	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2990897	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2990897	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2990897	shares
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5931608	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10159069	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022	BRAC	Public Right Description PublicRightDescription	Except in cases where the Company is not the surviving company in a Business Combination, each holder of a Public Right will automatically receive one-tenth (1/10) of one share of common stock upon consummation of a Business Combination, even if the holder of a Public Right converted all shares held by him, her or it in connection with a Business Combination or an amendment to the Company’s Amended and Restated Certificate of Incorporation with respect to its pre-business combination activities. In the event that the Company will not be the surviving company upon completion of a Business Combination, each holder of a Public Right will be required to affirmatively convert his, her or its rights in order to receive the one-tenth (1/10) of a share underlying each Public Right upon consummation of the Business Combination.

Files In Submission

Name	View Source	Status
0001493152-23-017112-index-headers.html	Edgar Link	pending
0001493152-23-017112-index.html	Edgar Link	pending
0001493152-23-017112.txt	Edgar Link	pending
0001493152-23-017112-xbrl.zip	Edgar Link	pending
brac-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brac-20230331_def.xml	Edgar Link	unprocessable
brac-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
brac-20230331_cal.xml	Edgar Link	unprocessable
brac-20230331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRAC
Broad Capital Acquisition Corp Stock $brac

2023 Q2 Form 10-Q Financial Statement

#000149315223017112 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRAC Broad Capital Acquisition Corp Stock $brac

2023 Q2 Form 10-Q Financial Statement

#000149315223017112 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRAC
Broad Capital Acquisition Corp Stock $brac